Rallybio Corporation (RLYB)
RLYB Stock Price Chart
Explore Rallybio Corporation interactive price chart. Choose custom timeframes to analyze RLYB price movements and trends.
RLYB Company Profile
Discover essential business fundamentals and corporate details for Rallybio Corporation (RLYB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Jul 2021
Employees
15.00
Website
https://www.rallybio.comCEO
Stephen Uden
Description
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
RLYB Financial Timeline
Browse a chronological timeline of Rallybio Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$1.28, while revenue estimate is $216.48k.
Earnings released on 13 May 2026
EPS came in at -$1.46 falling short of the estimated -$1.20 by -21.67%, while revenue for the quarter reached $212.00k , meeting expectations.
Earnings released on 12 Mar 2026
EPS came in at -$1.11 surpassing the estimated -$1.24 by +10.48%, while revenue for the quarter reached $222.00k , beating expectations by +122.00%.
Stock split effective on 6 Feb 2026
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 Nov 2025
EPS came in at -$0.14 surpassing the estimated -$0.25 by +44.00%, while revenue for the quarter reached $212.00k , beating expectations by +218.00%.
Earnings released on 7 Aug 2025
EPS came in at -$0.22 falling short of the estimated -$0.20 by -12.82%, while revenue for the quarter reached $212.00k , beating expectations by +217.98%.
Earnings released on 8 May 2025
EPS came in at -$0.21 matching the estimated -$0.21, while revenue for the quarter reached $212.00k .
Earnings released on 13 Mar 2025
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%, while revenue for the quarter reached $38.00k , missing expectations by -74.58%.
Earnings released on 7 Nov 2024
EPS came in at -$0.26 surpassing the estimated -$0.36 by +27.78%, while revenue for the quarter reached $299.00k , beating expectations by +298.67%.
Earnings released on 8 Aug 2024
EPS came in at -$0.37 surpassing the estimated -$0.42 by +11.90%, while revenue for the quarter reached $299.00k .
Earnings released on 9 May 2024
EPS came in at -$0.47 surpassing the estimated -$0.50 by +6.00%.
Earnings released on 12 Mar 2024
EPS came in at -$0.50 falling short of the estimated -$0.44 by -13.64%, while revenue for the quarter reached $228.00k .
Earnings released on 9 Nov 2023
EPS came in at -$0.45 surpassing the estimated -$0.51 by +11.76%.
Earnings released on 8 Aug 2023
EPS came in at -$0.46 surpassing the estimated -$0.48 by +4.17%.
Earnings released on 9 May 2023
EPS came in at -$0.43 surpassing the estimated -$0.50 by +14.00%.
Earnings released on 6 Mar 2023
EPS came in at -$0.46 surpassing the estimated -$0.63 by +26.98%.
Earnings released on 7 Nov 2022
EPS came in at -$0.60 falling short of the estimated -$0.54 by -11.11%.
Earnings released on 8 Aug 2022
EPS came in at -$0.57 surpassing the estimated -$0.61 by +6.56%.
Earnings released on 10 May 2022
EPS came in at -$0.48 matching the estimated -$0.48.
Earnings released on 15 Mar 2022
EPS came in at -$0.42 falling short of the estimated -$0.39 by -7.69%.
Earnings released on 10 Nov 2021
EPS came in at -$0.37 surpassing the estimated -$0.89 by +58.43%.
Earnings released on 9 Sept 2021
EPS came in at -$2.80 matching the estimated -$2.80.
RLYB Stock Performance
Access detailed RLYB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
